奥马珠单抗在慢性诱导性荨麻疹治疗中的应用进展
Progress in the application of omalizumab in the treatment of chronic inducible urticaria
陈紫嫣 1邹荟 1林天一 1吴伟鸿 1陈教全 2梁碧华 2李润祥 2李华平 2朱慧兰2
作者信息
- 1. 广州市皮肤病医院,广东 广州 510095;广州医科大学,广东 广州 511495
- 2. 广州市皮肤病医院,广东 广州 510095
- 折叠
摘要
慢性诱导性荨麻疹(CIndU)是由独特诱因诱发的以风团、血管性水肿为常见症状的慢性荨麻疹.奥马珠单抗是一种重组人源化的抗IgE抗体,目前国际指南将其列为CIndU的三线治疗,现已有部分奥马珠单抗治疗CIndU的先例,但相关的剂量、疗效、不良反应等数据相对不足.本文旨在对奥马珠单抗在各型CIndU治疗中的疗效及治疗进展进行综述,为CIndU患者提供治疗的理论基础.
Abstract
Chronic inducible urticaria(CIndU)is a chronic urticaria caused by unique trig-gers,manifested by wheals and angioedema as common symptoms.Omalizumab is a recombinant humanized anti-IgE antibody,which is currently listed as the third-line treatment for CIndU in in-ternational guidelines,and there are some precedents for the treatment of CIndU with omalizumab,but the relevant dose,efficacy,adverse reactions and other data are relatively insufficient.The purpose of this article is to review the efficacy and treatment progress of omalizumab in the treat-ment of various types of CIndU,and to provide a rationale for the treatment of patients with CIndU.
关键词
奥马珠单抗/慢性诱导性荨麻疹/皮肤划痕征/冷接触性荨麻疹/胆碱能性荨麻疹/延迟压力性荨麻疹Key words
omalizumab/chronic inducible urticaria/dermographia/cold contact urticaria/cholinergic urticaria/delayed-pressure urticaria引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据